Traitomic
Traitomic is a Danish biotechnology company that develops commercially valuable genetic traits across plants and microorganisms. Spun out of the Carlsberg Research Laboratory, it builds on more than a century of research in brewing, genetics and biological innovation. Traitomic’s traits address challenges across food, agriculture and industrial biotechnology, from improving yield, nutrition and flavor to optimizing processing.
To date, the company has delivered 116 traits to 47 customers across 32 organisms. Through TraitSource, it also gives researchers easy access to its active trait libraries, which continue to grow.
Sector
Industrial Biotech
Strategies
Status
Live
Website
www.traitomic.com
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.